Samjin Pharmaceutical Company

Samjin Pharmaceutical Company, established in 1968 and headquartered in Seoul, Korea, specializes in the research and development of pharmaceutical products. The company focuses on addressing significant health challenges, including dry eye syndrome, HIV, cancer, age-related macular degeneration, and central nervous system disorders. Its product pipeline features several candidates at various stages of development, such as SA001, a clinical Phase II treatment for dry eye syndrome, and SJ-3366, which targets HIV in preclinical and clinical stages. Additionally, Samjin's portfolio includes multiple preclinical and clinical products aimed at treating cancer, rheumatoid arthritis, diabetes, Alzheimer's disease, and anti-coagulation conditions. The company is committed to advancing healthcare by leveraging skilled personnel, innovative materials, and state-of-the-art medical technology to develop effective treatments for various diseases.

Choi Yong-ju

Co-President, CEO and Director

1 past transactions

Neurophet

Corporate Round in 2024
Neurophet, Inc. is a neuroscience company based in Seoul, South Korea, founded in 2016. It specializes in developing innovative software solutions for brain stimulation and treatment of neurological disorders. The company's flagship product, Neurophet tES Lab, is a simulation software that calculates and visualizes the effects of brain stimulation by utilizing individual brain structures and specific stimulation conditions. Neurophet employs its proprietary Segengine technology, which can automatically segment brain magnetic resonance images into 107 distinct regions within a minute. This technology aids in predicting and investigating stimulation effects for conditions such as Alzheimer's disease, providing clinicians with a three-dimensional brain model and stimulation parameter guidance. By leveraging deep learning and numerical optimization techniques, Neurophet enables healthcare professionals to focus interventions on targeted regions of the brain, enhancing treatment efficacy for patients with brain diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.